DaVita Inc (DVA) has seen its stock price drop significantly, hitting a 52-week low amid a broader decline in the healthcare sector, which is down 0.5% today.
The healthcare sector's struggles are reflected in DaVita's performance, with the company experiencing a decline of 4.2%. This drop is part of a larger trend affecting the financial sector, which is down 0.7%, and may be contributing to investor concerns about the healthcare industry's stability. The overall market sentiment is negative, with major indices like the Nasdaq-100 and S&P 500 also showing declines.
Investors are closely monitoring the situation as the healthcare sector's performance could influence future investment decisions. The decline in DaVita's stock may lead to increased scrutiny from analysts and investors alike.
Wall Street analysts forecast DVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DVA is 136.50 USD with a low forecast of 130.00 USD and a high forecast of 143.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast DVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DVA is 136.50 USD with a low forecast of 130.00 USD and a high forecast of 143.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
3 Hold
1 Sell
Hold
Current: 105.880
Low
130.00
Averages
136.50
High
143.00
Current: 105.880
Low
130.00
Averages
136.50
High
143.00
Truist
David MacDonald
Hold
maintain
$128 -> $140
2026-01-05
Reason
Truist
David MacDonald
Price Target
$128 -> $140
AI Analysis
2026-01-05
maintain
Hold
Reason
Truist analyst David MacDonald raised the firm's price target on DaVita to $140 from $128 and keeps a Hold rating on the shares. Despite the non-discretionary nature of the service and solid cash flow, improving volume trends remain critical amid a mixed environment marked by sluggish admissions, mortality, and missed treatments, the analyst tells investors in a research note.
TD Cowen
Gary Taylor
Hold
downgrade
$154 -> $133
2025-11-03
Reason
TD Cowen
Gary Taylor
Price Target
$154 -> $133
2025-11-03
downgrade
Hold
Reason
TD Cowen analyst Gary Taylor lowered the firm's price target on DaVita to $133 from $154 and keeps a Hold rating on the shares. The firm noted they missed 3Q25 EBIT by -10%, but they attribute a portion to Street mis-modeling while the recent pullback has Dthe shares shares looking more appealing, but a continued tepid volume outlook offsets upside.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DVA
Unlock Now
Barclays
Equal Weight
maintain
$149 -> $143
2025-10-30
Reason
Barclays
Price Target
$149 -> $143
2025-10-30
maintain
Equal Weight
Reason
Barclays lowered the firm's price target on DaVita to $143 from $149 and keeps an Equal Weight rating on the shares post the Q3 report. The firm says an "unusual quarterly progression" drove a large disparity between DaVita's internal plan and Street estimates, resulting in a big headline miss but guidance reiteration.
Truist
David MacDonald
Hold
downgrade
$148 -> $140
2025-10-14
Reason
Truist
David MacDonald
Price Target
$148 -> $140
2025-10-14
downgrade
Hold
Reason
Truist analyst David MacDonald lowered the firm's price target on DaVita to $140 from $148 and keeps a Hold rating on the shares as part of a broader research note previewing Q3 results in Healthcare Service. The firm is "broadly bullish" on the industry as it expects ongoing strength in core demand drivers and continues to like the long-term positioning of covered names within their sector verticals, coupled with improved visibility around the regulatory environment, the analyst tells investors in a research note. Strong free cash flows and attractive financial flexibility across the bulk of the sector underpins the ongoing growth investment, Truist notes, adding that it sees a "brisk opportunity" to deploy capital to further augment core growth and drive M&A.
About DVA
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
